In a groundbreaking development, the results of the randomized phase 3 PAPILLON study have shown that the combination of amivantamab, carboplatin, and pemetrexed has led to significant improvements in progression-free survival (PFS) for patients with non-small cell lung cancer (NSCLC) and an EGFR exon 20 insertion. This is a major breakthrough in the treatment of this specific population, as previous therapies have not shown significant efficacy in this subgroup.
The study revealed that the combination therapy resulted in not only improved PFS, but also a higher overall response rate, a longer duration of response, and a promising trend towards overall survival benefit when compared to chemotherapy alone. This is particularly significant as patients with EGFR exon 20 insertion NSCLC have historically faced poor outcomes and limited treatment options.
Amivantamab, a bispecific antibody targeting EGFR and MET, has shown great promise in treating NSCLC and has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for patients with EGFR exon 20 insertion-positive metastatic NSCLC who have progressed on platinum-based chemotherapy. The addition of carboplatin and pemetrexed to this therapy further enhances its efficacy and provides hope for patients in need of effective treatment options.
The findings of the PAPILLON study mark a significant advancement in the field of lung cancer treatment, offering new hope to patients with EGFR exon 20 insertion NSCLC. The combination therapy of amivantamab, carboplatin, and pemetrexed not only improves progression-free survival but also shows potential for increasing overall survival. These results underscore the importance of continued research and development in targeted therapies for specific genetic mutations, ultimately leading to better outcomes and improved quality of life for lung cancer patients.
Read more at Targeted Oncology
By![A person sits on a blue chair during a discussion at an event. They appear thoughtful, wearing a dark jacket and a light shirt, with a blue backdrop featuring the text "HUMAN[x]."](https://biztechweekly.com/wp-content/uploads/2025/07/metas-14.3b-scale-ai-investment-sparks-surge-in-competitor-growth-and-client-shifts-in-ai-training-market-870x570.webp)
By
By
By
By
